Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). In a filing disclosed on May 06th, the Representative disclosed that they had bought between $1,001 and $15,000 in Agios Pharmaceuticals stock on April 17th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of Beiersdorf Aktiengesellschaft OTCMKTS: BDRFF on 5/2/2025.
• Purchased $1,001 - $15,000 in shares of Alkami Technology NASDAQ: ALKT on 4/30/2025.
• Purchased $1,001 - $15,000 in shares of Merck & Co., Inc. NYSE: MRK on 4/29/2025.
• Sold $1,001 - $15,000 in shares of DXC Technology NYSE: DXC on 4/29/2025.
• Sold $1,001 - $15,000 in shares of DOW NYSE: DOW on 4/29/2025.
• Sold $1,001 - $15,000 in shares of Zions Bancorporation, National Association NASDAQ: ZION on 4/29/2025.
• Purchased $1,001 - $15,000 in shares of O'Reilly Automotive NASDAQ: ORLY on 4/29/2025.
• Purchased $1,001 - $15,000 in shares of McKesson NYSE: MCK on 4/29/2025.
• Sold $1,001 - $15,000 in shares of Amazon.com NASDAQ: AMZN on 4/29/2025.
• Sold $1,001 - $15,000 in shares of Humana NYSE: HUM on 4/29/2025.

Agios Pharmaceuticals Price Performance

Shares of AGIO stock traded down $0.72 during mid-day trading on Friday, hitting $27.32. The stock had a trading volume of 303,182 shares, compared to its average volume of 696,244. The firm has a market cap of $1.58 billion, a PE ratio of 2.41 and a beta of 0.77. The company's 50-day simple moving average is $29.23 and its 200-day simple moving average is $37.22. Agios Pharmaceuticals, Inc. has a fifty-two week low of $23.42 and a fifty-two week high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($1.55) EPS for the quarter, beating analysts' consensus estimates of ($1.80) by $0.25. Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. The firm had revenue of $8.73 million during the quarter, compared to the consensus estimate of $9.86 million. On average, analysts expect that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current year.

Insider Buying and Selling at Agios Pharmaceuticals

In other news, Director Jacqualyn A. Fouse sold 7,497 shares of the firm's stock in a transaction on Thursday, April 10th. The stock was sold at an average price of $25.90, for a total transaction of $194,172.30. Following the sale, the director now owns 149,220 shares in the company, valued at $3,864,798. This trade represents a 4.78 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 4.93% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Franklin Resources Inc. acquired a new stake in Agios Pharmaceuticals during the 3rd quarter valued at $1,499,000. Nordea Investment Management AB boosted its stake in shares of Agios Pharmaceuticals by 3.6% during the fourth quarter. Nordea Investment Management AB now owns 220,569 shares of the biopharmaceutical company's stock valued at $7,191,000 after acquiring an additional 7,593 shares during the last quarter. Contravisory Investment Management Inc. acquired a new stake in shares of Agios Pharmaceuticals during the fourth quarter valued at $222,000. Inspire Investing LLC increased its position in Agios Pharmaceuticals by 34.2% during the 4th quarter. Inspire Investing LLC now owns 12,384 shares of the biopharmaceutical company's stock worth $407,000 after purchasing an additional 3,156 shares in the last quarter. Finally, KBC Group NV raised its stake in Agios Pharmaceuticals by 30.5% in the 4th quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company's stock valued at $86,000 after purchasing an additional 611 shares during the last quarter.

Analysts Set New Price Targets

A number of research analysts recently weighed in on AGIO shares. StockNews.com raised Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday. Scotiabank cut their price target on shares of Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating for the company in a report on Friday, May 2nd. Finally, HC Wainwright began coverage on shares of Agios Pharmaceuticals in a report on Monday, February 24th. They set a "buy" rating and a $58.00 price objective on the stock. Five analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $56.00.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.